The Partnership Tree Logo
 
 
 
 
 
 
absci Logo  
 
 
Partner Profile
 
If you'd like to claim this company profile for absci, please Contact Us.
 

absci News

The latest news, announcements and press releases from absci.

 
 
25
January
2025
25th January 2025
 

Absci and Owkin synergise TechBio platforms to advance AI drug discovery

Absci Corporation, a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, have announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients. 

 
Read the full story »
 
 
15
August
2024
15th August 2024
 

Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI

VANCOUVER, Wash. and NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Today, Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK), a leading cancer treatment and research center, to discover and develop novel therapeutics using generative AI for up to six programs. Under the terms of the collaboration, Absci and MSK’s world-renowned cancer research teams will co-develop therapeutics using Absci’s Integrated Drug Creation™ platform.


“MSK has an incredible record of groundbreaking translational and clinical innovations in oncology,” said Sean McClain, Founder & CEO of Absci. “By combining MSK’s research expertise with our generative AI drug creation platform, we have the potential to unlock critical advances toward treating this devastating disease.”


“At MSK, we are committed to continuous innovation as we strive toward our mission of ending cancer for life, and we expect cancer care AI to play an increasingly important role,” said Gregory Raskin, MD, Senior Vice President of Technology Development at MSK. “We look forward to collaborating with Absci in leveraging the company’s generative AI platform in our ongoing efforts to advance cancer research and develop new therapies for our patients.”


The new collaboration adds to Absci’s roster of research and drug development collaborations designed to develop novel biologics for debilitating diseases. In the last year, Absci has joined forces with global pharma leaders and research institutes, including AstraZeneca and Almirall, alongside existing collaborations with Merck, NVIDIA and others. In addition to drug creation partnerships, Absci continues to develop a pipeline of internal drug candidates, including ABS-101, a potential best-in-class anti-TL1A antibody, designed and optimized using generative AI.

 
Read the full story »
 
 
04
December
2023
04th December 2023
 

Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate

Collaboration Combines Absci’s AI Antibody Drug Creation Platform with AstraZeneca’s Expertise in Oncology Research and Development

 
Read the full story »
 
 
 

Claim This Profile

This is the News section of the company profile page for absci on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.

 
 
absci company details, activities, contacts and reviews.
 
absci documents, images and videos.
 
absci partnership and licensing opportunities.
 
absci latest news, announcements and press releases.
 
absci global factories, offices and locations.
 
absci legal and financial information.
 
absci blogs, articles and journal posts.
 
 
 
 
 
 
 

About Us

The Partnership Tree established in 2003 (initially a pharmaceutical company directory) supporting companies in the finding, qualification and management of quality vendors and technical partners in the pharmaceutical. biotech and medical devices industry.

The Partnership Tree supports the finding and egagement with technical and commercial partners. It also incorporates software applications that support successful partner engagement and management. These include the building and deployment of questionnaires and assessments for vendor qualification, document excahnge, electronic signatures and sign-offs and project management between vendor/partner and customer.

Access to the features and software is available on a 'pay as you go' basis, or a customised version can be licensed for your company for its own on-boarding and supplier management activities. Further information on our software services can be found at www.thepartnersplatform.com 

 
 
 

Get in Touch

The Partnership Tree   paul@thepartnersplatform.com

 
 

© 2025 The Partnership Tree | All Rights Reserved.